Head-To-Head Contrast: RTI Surgical (RTIX) versus Its Competitors
RTI Surgical (NASDAQ: RTIX) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it weigh in compared to its competitors? We will compare RTI Surgical to similar businesses based on the strength of its valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and profitability.
This table compares RTI Surgical and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|RTI Surgical Competitors||-101.23%||-92.70%||-30.32%|
Earnings & Valuation
This table compares RTI Surgical and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|RTI Surgical||$272.86 million||-$14.39 million||-61.43|
|RTI Surgical Competitors||$1.67 billion||$207.58 million||64.92|
RTI Surgical’s competitors have higher revenue and earnings than RTI Surgical. RTI Surgical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
69.9% of RTI Surgical shares are held by institutional investors. Comparatively, 54.8% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 4.9% of RTI Surgical shares are held by company insiders. Comparatively, 10.3% of shares of all “Medical Devices & Implants” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for RTI Surgical and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|RTI Surgical Competitors||112||732||1028||10||2.50|
As a group, “Medical Devices & Implants” companies have a potential upside of 39.21%. Given RTI Surgical’s competitors higher possible upside, analysts clearly believe RTI Surgical has less favorable growth aspects than its competitors.
Volatility and Risk
RTI Surgical has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Comparatively, RTI Surgical’s competitors have a beta of 0.21, indicating that their average share price is 79% less volatile than the S&P 500.
RTI Surgical beats its competitors on 6 of the 10 factors compared.
RTI Surgical Company Profile
RTI Surgical, Inc. is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company’s business primarily consists of six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties. It processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing BIOCLEANSE, TUTOPLAST and CANCELLE SP sterilization processes, and manufactures metal and synthetic implants for distribution to hospitals and surgeons. The Company distributes its implants and services in approximately 50 states and in over 45 countries across the world.
Receive News & Ratings for RTI Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTI Surgical and related companies with Analyst Ratings Network's FREE daily email newsletter.